EU Regulators Concerned By Mushrooming Of Small COVID-19 Trials
Want Better Use Of The Short Window Of Opportunity
Executive Summary
Based on experience from earlier epidemics, EU regulators are concerned that the high number of COVID-19 trials starting in a confined geography at the peak of the coronavirus pandemic will not be able to enrol patients up to their pre-established sample size.
You may also be interested in...
EU Platform Trials Project Piques WHO’s Interest
The World Health Organization is developing a new best practice guideline on improving the quality and efficiency of clinical trials and is keen to learn what role platform trials can play on this front and their acceptability by the clinical trial community.
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.